We have embarked on an ambitious transformation to become the leading medicines company powered by data science and digital technologies. Novartis partnering interests around AI platforms aim to:
- Artificial intelligence/Machine learning (AI/ML) approaches to accelerate discovery and synthesis of new molecular entities
- Automated synthesis and profiling platforms
- Novel cyclic peptide screening platforms
Avi Spier
- Novel approaches/platforms that leverage AI/ML and wet lab capabilities for challenging and multi-specific antibody discovery.
- Targeted delivery and selective tropism to key tissues/cell types
- Biodistribution, intracellular trafficking and stability assessment of Adeno-associated virus (AAV), Radioligand therapeutics (RLTs), and targeted siRNA conjugates
Gianfranco de Pascale
- Targeted delivery approaches for RNA therapeutics to extra-hepatic tissues/cell types
- Innovative siRNA chemistry platforms
- In vivo/In vitro platforms to identify and validate siRNA targets
Gianfranco de Pascale
- Differentiated RLT assets that complement current pipeline and disease focus with novel isotopes, chelators or vectors for tumor specific RLT delivery
- Explore various combination approaches which are synergistic with RLTs
- Technologies to expand the therapeutic window of RLTs
Shona Whyte
We have embarked on an ambitious transformation to become the leading medicines company powered by data science and digital technologies. Novartis partnering interests around AI platforms aim to:
- Enable deeper understanding of disease to identify novel therapeutic Targets
- Power small and large molecule design and optimization
- Increase predictive safety
- Improve trial design and execution
